Vimta Labs Shares Surge 7% Following Strong Q4; Revenue Hits Record Highs

Synopsis: Vimta Labs is in the spotlight today, May 7, 2026, after reporting a robust 19.5% jump in annual revenue for FY26. The contract research leader has impressed investors with strong profit growth and high margins, triggering a significant rally in its share price.

In a regulatory filing and investor presentation submitted to the NSE and BSE, Vimta Labs Limited announced its audited financial results for the quarter and full year ended March 31, 2026. 

The company reported a total income of ₹112.0 crore for Q4 FY26, marking a 16.6% year-on-year growth. On a full-year basis, the company achieved its highest-ever revenue of ₹416.3 crore, compared to ₹3,482 million in the previous fiscal year, driven by strong demand in its pharmaceutical and food testing segments.

The company’s profitability remained healthy, with a consolidated Net Profit (PAT) of ₹77.5 crore for FY26, up from ₹66.8 crore in FY25. Operating EBITDA margins for the fourth quarter stood at a solid 37.6%, despite an exceptional statutory impact of ₹1.6 crore related to new Labour Codes.

Management noted that the company’s leadership in the Pharma Analytical and Food Testing sectors serving 90% of India’s top 20 pharma firms continues to drive operational excellence. Looking forward, the company is focusing on capacity expansions and electronics certification to capitalize on the “Make in India” initiative.

Following the announcement of the record-breaking results, Vimta Labs shares witnessed strong buying interest on the NSE. During the morning session on May 7, 2026, the stock surged by 7.32%, trading at ₹548.05 per share. This rally comes as a welcome relief for investors, as the stock had previously hit a 52-week low of ₹376.05 in late March 2026.

The company currently commands a market capitalization of approximately ₹2,431.8 crore. With a very low debt-to-equity ratio of 0.01 and cash equivalents of over ₹65.0 crore, the market is reacting positively to Vimta’s financial stability and growth outlook. The stock has delivered an absolute return of nearly 20% over the last week, significantly outperforming the broader Nifty 50 index.

Vimta Labs Limited is India’s leading contract research and testing organization (CRTO), headquartered in Hyderabad. Established in 1984, the company provides a comprehensive range of technical services to the pharmaceutical, biopharmaceutical, food, and electronics industries. With over 600,000 square feet of state-of-the-art laboratory infrastructure and a team of 1,300+ professionals, Vimta is a dominant player in drug discovery, clinical research, and analytical testing, maintaining a successful regulatory track record with global bodies like the USFDA and WHO.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing. 

The post Vimta Labs Shares Surge 7% Following Strong Q4; Revenue Hits Record Highs appeared first on Trade Brains.